Abstract
Rania Boulesbiaat1*, Sébastien Mosser2, Arnaud Porta3, Karl Heinz Krause4 and JM Leroux5 Author Affiliations 1Sativalp Pharmaceuticals SA, Route de Lavaux 296, 1095 Lutry, Switzerland 2Neurix, Switzerland 3Sativalp Pharmaceuticals SA, Route de Lavaux 296, 1095 Lutry, Switzerland 4Faculty of Medicine Geneva, Switzerland 5University of Geneva, Switzerland Received: May 23, 2022 | Published: June 03, 2022 Corresponding author: Rania Boulesbiaat, Sativalp Pharmaceuticals SA, Route de Lavaux 296, 1095 Lutry, Switzerland DOI: 10.26717/BJSTR.2022.44.007030
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Biomedical Journal of Scientific & Technical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
